1. CRDF presents Phase 2 data on onvansertib for mCRC treatment. 2. High-dose onvansertib shows a 59% objective response rate. 3. William Blair supports further investment and a Phase 3 trial. 4. Current valuation reflects skepticism towards onvansertib's profile. 5. CRDF shares fell nearly 20% on the news.
Despite a short-term drop, the trial results highlight onvansertib's effectiveness, which can lead to long-term valuation recovery, similar to previous oncology trials where promising results reversed initial stock declines.
The positive response rates from onvansertib may shift future investor sentiment, akin to historical trends seen in successful oncology drug developments.
The ongoing efficacy validation in clinical trials can lead to regulatory approval, impacting CRDF positively over the long-term, much like what happened with successful oncology drugs in the past.